Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

Exclusion Criteria

• •1. Retinal diseases (including diabetic retinopathy, retinal vein or artery occlusion, neovascular age-related macular degeneration, radiation retinopathy, vitreomacular traction, epiretinal membrane).
• •2. Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye.
• •3. Active infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye.
• •4. Prior treatment with sub-Tenon's or intravitreal steroids.
• •5. Prior treatment with an intravitreal anti-vascular endothelial growth factor (VEGF) agent in the study eye or systemic administration of anti-VEGF.
• •6. Use of topical prostaglandin analogues or pilocarpine.
• •7. Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with glaucoma medications.
• •8. Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye.
• •9. Vision loss in the study eye, determined by the investigator to be from a cause other than CME, e.g. optic neuropathy, end-stage glaucoma.
• •10. Any significant media opacity including vitreous hemorrhage or corneal scarring.
• •11. Fluorescein dye allergy or intolerance
• •12. Allergy to aflibercept or any of the components
• •13. Cerebrovascular accident or myocardial infarction within 1 year of the screening visit.
• •14. Pregnant or breast-feeding women
• •15. Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception starting at least 2 menstrual cycles prior to the baseline visit, during the study and in the 3 months immediately following the last dose of study drug.